

BILL ANALYSIS

C.S.H.B. 597
By: Clardy
Criminal Jurisprudence
Committee Report (Substituted)

BACKGROUND AND PURPOSE

It has been reported that the increased presence of synthetic marihuana in Texas is causing growing concern due to the dangerous side effects of using the drug, including hallucinations, seizures, convulsions, and, in extreme cases, death. Interested parties note that synthetic marihuana is made in a lab and is different and more powerful than traditional marihuana. Some crime lab technicians have had difficulty proving that synthetic marihuana mimics the pharmacological effect of a naturally occurring cannabinoid because of insufficient research and literature regarding the effects of synthetic marihuana, which the parties contend has severely inhibited prosecutions across the state. Additionally, a skilled chemist may be able to change the chemical makeup of a substance enough to circumvent the law and make the law difficult to enforce. C.S.H.B. 597 seeks to address these issues.

CRIMINAL JUSTICE IMPACT

It is the committee's opinion that this bill does not expressly create a criminal offense, increase the punishment for an existing criminal offense or category of offenses, or change the eligibility of a person for community supervision, parole, or mandatory supervision.

RULEMAKING AUTHORITY

It is the committee's opinion that this bill does not expressly grant any additional rulemaking authority to a state officer, department, agency, or institution.

ANALYSIS

C.S.H.B. 597 amends the Health and Safety Code to change the substances listed in Penalty Group 2-A of the Texas Controlled Substances Act from any quantity of a synthetic chemical compound that is a cannabinoid receptor agonist and mimics the pharmacological effect of naturally occurring cannabinoids to any material, compound, mixture, or preparation that contains any quantity of certain natural or synthetic chemical substances listed by name or contained within one of the structural classes defined by the bill. The bill revises the controlled substances listed and defines certain chemical structural classes in Penalty Group 2-A. The bill establishes that Penalty Group 2-A, for the purposes of the prosecution of an offense under the Texas Controlled Substances Act involving the manufacture, delivery, or possession of a controlled substance, includes a controlled substance analogue that has a chemical structure substantially similar to the chemical structure of a controlled substance listed in Penalty Group 2-A or is specifically designed to produce an effect substantially similar to, or greater than, a controlled substance in Penalty Group 2-A.

EFFECTIVE DATE

September 1, 2015.

COMPARISON OF ORIGINAL AND SUBSTITUTE

While C.S.H.B. 597 may differ from the original in minor or nonsubstantive ways, the following comparison is organized and formatted in a manner that indicates the substantial differences between the introduced and committee substitute versions of the bill.

INTRODUCED	HOUSE COMMITTEE SUBSTITUTE
SECTION 1. Sections 481.002(5) and (6), Health and Safety Code, are amended.	SECTION 1. Same as introduced version.
SECTION 2. Section 481.1031, Health and Safety Code, is amended to read as follows: Sec. 481.1031. PENALTY GROUP 2-A.	SECTION 2. Section 481.1031, Health and Safety Code, is amended to read as follows: Sec. 481.1031. PENALTY GROUP 2-A. (a) In this section: (1) "Core component" is one of the following: azaindole, benzimidazole, benzothiazole, carbazole, imidazole, indane, indazole, indene, indole, pyrazole, pyrazolopyridine, pyridine, or pyrrole. (2) "Group A component" is one of the following: adamantane, benzene, cycloalkylmethyl, isoquinoline, methylpiperazine, naphthalene, phenyl, quinoline, tetrahydronaphthalene, tetramethylcyclopropane, amino oxobutane, amino dimethyl oxobutane, amino phenyl oxopropane, methyl methoxy oxobutane, methoxy dimethyl oxobutane, methoxy phenyl oxopropane, or an amino acid. (3) "Link component" is one of the following functional groups: carboxamide, carboxylate, hydrazide, methanone (ketone), ethanone, methanediyl (methylene bridge), or methine.
Penalty Group 2-A consists of <u>any material, compound, mixture, or preparation that contains any quantity of a synthetic chemical substance, including its salts, isomers, and salts of isomers, listed by name in this section or contained within the following structural classes defined in this section</u> [compound that is a cannabinoid receptor agonist and mimics the pharmacological effect of naturally occurring cannabinoids, including]: <u>WIN-55,212-2;</u>	(b) Penalty Group 2-A consists of <u>any material, compound, mixture, or preparation that contains any quantity of a natural or synthetic chemical substance, including its salts, isomers, and salts of isomers, listed by name in this subsection or contained within one of the structural classes defined in this subsection</u> : (1) WIN-55,212-2; (2) Cyclohexylphenol: <u>any compound</u> [that is a cannabinoid receptor agonist and mimics the pharmacological effect of naturally occurring cannabinoids, including] [<u>naphthoylindoles</u> structurally derived from
<u>Naphthoylindole: any compound</u> [<u>naphthoylindoles</u>] <u>structurally derived from</u>	[<u>naphthoylindoles</u> structurally derived from

3-(1-naphthoyl)indole or 3-(2-naphthoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl [2-(4-morpholinyl)ethyl], whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ~~[naphthyl]~~ ring to any extent, including:

AM-1220;
AM-2201;
JWH-004;
JWH-007;
JWH-009;
JWH-015;
JWH-016;
JWH-018;
JWH-019;
JWH-020;
JWH-046;
JWH-047;
JWH-048;
JWH-049;
JWH-050;
JWH-073;
JWH-076;
JWH-079;
JWH-080;
JWH-081;
JWH-082;
JWH-083;
JWH-093;
JWH-094;
JWH-095;
JWH-096;
JWH-097;
JWH-098;
JWH-099;
JWH-100;
JWH-116;
JWH-122;
JWH-148;
JWH-149;
JWH-153;
JWH-159;
JWH-164;
JWH-165;
JWH-166;
JWH-180;
JWH-181;
JWH-182;

~~3-(1-naphthoyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:~~

[AM 2201;
[JWH 004;
[JWH 007;
[JWH 009;
[JWH 015;
[JWH 016;
[JWH 018;
[JWH 019;
[JWH 020;
[JWH 046;
[JWH 047;
[JWH 048;
[JWH 049;
[JWH 050;
[JWH 073;
[JWH 076;
[JWH 079;
[JWH 080;
[JWH 081;
[JWH 082;
[JWH 083;
[JWH 093;
[JWH 094;
[JWH 095;
[JWH 096;
[JWH 097;
[JWH 098;
[JWH 099;
[JWH 100;
[JWH 116;
[JWH 122;
[JWH 148;
[JWH 149;
[JWH 153;
[JWH 159;
[JWH 164;
[JWH 165;
[JWH 166;
[JWH 180;
[JWH 181;
[JWH 182;

JWH-189;
JWH-193;
JWH-198;
JWH-200;
JWH-210;
JWH-211;
JWH-212;
JWH-213;
JWH-234;
JWH-235;
JWH-239;
JWH-240;
JWH-241;
JWH-242;
JWH-258;
JWH-259;
JWH-260;
JWH-262;
JWH-267;
JWH-386;
JWH-387;
JWH-394;
JWH-395;
JWH-397;
JWH-398;
JWH-399;
JWH-400;
JWH-412;
JWH-413; and
JWH-414;

Naphthylmethylindole: any compound [naphthylmethylindones] structurally derived from 1H-indol-3-yl-(1-naphthyl)methane or 1H-indol-3-yl-(2-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl [2-(4-morpholinyl)ethyl], whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:

JWH-175;
JWH-184;
JWH-185;
JWH-192;
JWH-194;
JWH-195;
JWH-196;
JWH-197; and
JWH-199;

[JWH-189;
JWH-193;
JWH-198;
JWH-200;
JWH-210;
JWH-211;
JWH-212;
JWH-213;
JWH-234;
JWH-235;
JWH-239;
JWH-240;
JWH-241;
JWH-242;
JWH-258;
JWH-259;
JWH-260;
JWH-262;
JWH-267;
JWH-386;
JWH-387;
JWH-394;
JWH-395;
JWH-397;
JWH-398;
JWH-399;
JWH-400;
JWH-412;
JWH-413; and
JWH-414;

[naphthylmethylindones structurally derived from 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:

[JWH-175;
JWH-184;
JWH-185;
JWH-192;
JWH-194;
JWH-195;
JWH-196;
JWH-197; and
JWH-199;

Naphthylindolecarboxamide: any compound structurally derived from N-(naphthalen-1-yl)-1H-indole-3-carboxamide or N-(naphthalen-2-yl)-1H-indole-3-carboxamide by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:

MN-24 (Other name: NNEI);

Naphthoylpyrrole: any compound [naphthoylpyrroles] structurally derived from 3-(1-naphthoyl)pyrrole or 3-(2-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl [2-(4-morpholinyl)ethyl], whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:

JWH-030;
JWH-145;
JWH-146;
JWH-147;
JWH-150;
JWH-156;
JWH-243;
JWH-244;
JWH-245;
JWH-246;
JWH-292;
JWH-293;
JWH-307;
JWH-308;
JWH-309;
JWH-346;
JWH-347;
JWH-348;
JWH-363;
JWH-364;
JWH-365;
JWH-366;
JWH-367;
JWH-368;
JWH-369;
JWH-370;

[naphthoylpyrroles structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:

[JWH-030;
JWH-145;
JWH-146;
JWH-147;
JWH-150;
JWH-156;
JWH-243;
JWH-244;
JWH-245;
JWH-246;
JWH-292;
JWH-293;
JWH-307;
JWH-308;
JWH-309;
JWH-346;
JWH-347;
JWH-348;
JWH-363;
JWH-364;
JWH-365;
JWH-366;
JWH-367;
JWH-368;
JWH-369;
JWH-370;

JWH-371;
JWH-372;
JWH-373; and
JWH-392;

Naphthylmethylindene: any compound [naphthylmethylindenes] structurally derived from 1-(1-naphthylmethyl)indene or 1-(2-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl [2-(4-morpholinyl)ethyl], whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:

JWH-171;
JWH-172;
JWH-173; and
JWH-176;

Phenylacetylindole: any compound [phenylacetylindoles] structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl [2-(4-morpholinyl)ethyl], whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent, including:

[AM-694;
[AM-1241;]

JWH-167;
JWH-203;
JWH-204;
JWH-205;
JWH-206;
JWH-208;
JWH-237;
JWH-248;
JWH-249;
JWH-250;
JWH-251;
JWH-252;
JWH-253;
JWH-302;
JWH-303;
JWH-305;

[JWH-371;
[JWH-372;
[JWH-373; and
[JWH-392;

[naphthylmethylindenes structurally derived from 1-(1-naphthylmethyl)indene by substitution at the 3-position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent, including:

[JWH-171;
[JWH-172;
[JWH-173; and
[JWH-176;

[phenylacetylindoles structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent, including:

[AM-694;
[AM-1241;
[JWH-167;
[JWH-203;
[JWH-204;
[JWH-205;
[JWH-206;
[JWH-208;
[JWH-237;
[JWH-248;
[JWH-249;
[JWH-250;
[JWH-251;
[JWH-252;
[JWH-253;
[JWH-302;
[JWH-303;
[JWH-305;

JWH-306;
JWH-311;
JWH-312;
JWH-313;
JWH-314; [and]
JWH-315; and
RCS-8;

[JWH-306;
JWH-311;
JWH-312;
JWH-313;
JWH-314; and
JWH-315;

Benzoylindole: any compound structurally derived from 3-benzoylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent, including:

AM-630;
AM-679;
AM-694;
AM-1241;

Pravadoline (Other name: WIN 48,098); and
RCS-4;

Adamantoylindole: any compound structurally derived from 3-(1-adamantoyl)indole or 3-(2-adamantoyl)indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl ring to any extent, including:

AB-001; and
AM-1248;

Adamantylindolecarboxamide: any compound structurally derived from N-(adamantan-1-yl)-1H-indole-3-carboxamide or N-(adamantan-2-yl)-1H-indole-3-carboxamide by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the adamantyl

ring to any extent, including:
 APICA; and
 STS-135;
 Adamantylindazolecarboxamide: any compound structurally derived from N-(adamantan-1-yl)-1H-indazole-3-carboxamide or N-(adamantan-2-yl)-1H-indazole-3-carboxamide by substitution at the 1-position nitrogen atom of the indazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indazole ring to any extent, whether or not substituted in the adamantyl ring to any extent, including:
 5-Fluoro AKB-48; and
 AKB-48;
 Aminooxobutylindazolecarboxamide: any compound structurally derived from N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide by substitution at the 1-position nitrogen atom of the indazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indazole ring to any extent, including:
 AB-PINACA; and
 AB-FUBINACA;
 Tetramethylcyclopropylindole: any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl)indole by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or not further substituted in the indole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including:
 A-834,735;
 A-796,260;
 AB-005;
 UR-144;
 5-Bromo UR-144;

5-Chloro UR-144; and
5-Fluoro UR-144 (Other name: XLR-11);
Tetramethylcyclopropane-thiazole
carboxamide: any compound structurally
derived from 2,2,3,3-tetramethyl-N-(thiazol-
2-ylidene)cyclopropanecarboxamide by
substitution at the nitrogen atom of the
thiazole ring by alkyl, haloalkyl, benzyl,
halobenzyl, alkenyl, haloalkenyl, alkoxy,
cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-
yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-
morpholinyl)alkyl, whether or not further
substituted in the thiazole ring to any extent,
whether or not substituted in the
tetramethylcyclopropyl ring to any extent,
including:
A-836,339;

Quinolinyndolecarboxylate: any compound
structurally derived from quinolin-8-yl
indole-3-carboxylate by substitution at the
nitrogen atom of the indole ring with alkyl,
haloalkyl, benzyl, halobenzyl, alkenyl,
haloalkenyl, alkoxy, cyanoalkyl,
hydroxyalkyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-
yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-
morpholinyl)alkyl, whether or not further
substituted in the indole ring to any extent,
whether or not substituted in the quinoline
ring to any extent, including:

BB-22;

5-Fluoro PB-22; and

PB-22;

Cyclohexylphenol: any compound
[cyclohexylphenols] structurally derived
from 2-(3-hydroxycyclohexyl)phenol by
substitution at the 5-position of the phenolic
ring by alkyl, haloalkyl, benzyl, halobenzyl,
alkenyl, haloalkenyl, alkoxy, cyanoalkyl,
hydroxyalkyl, cycloalkylmethyl,
cycloalkylethyl, (N-methylpiperidin-2-
yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-
morpholinyl)alkyl [2-(4-morpholinyl)ethyl],
whether or not substituted in the cyclohexyl
ring to any extent, including:

CP-55,940;

CP-47,497;

analogues of CP-47,497, including VII, V,
VIII, I, II, III, IV, IX, X, XI, XII, XIII, XV,
and XVI;

JWH-337;

JWH-344;

[cyclohexylphenols] structurally derived
from 2-(3-hydroxycyclohexyl)phenol by
substitution at the 5-position of the phenolic
ring [by—alkyl], (N-methylpiperidin-2-
yl)alkyl, (4-tetrahydropyran)alkyl, or 2-(4-
morpholinyl)alkyl [alkenyl,
cycloalkylmethyl, cycloalkylethyl, or 2-(4-
morpholinyl)ethyl], whether or not
substituted in the cyclohexyl ring to any
extent, including:

JWH-337;

JWH-344;

CP-55,940;

CP-47,497; and

analogues of CP-47,497;

JWH-345; and
JWH-405; and
cannabinol

derivatives, except where contained in marihuana, including tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, such as:

Nabilone;
HU-210; and
HU-211[; and

(3) Cannabinol[, including VII, V, VIII, I, II, III, IV, IX, X, XI, XII, XIII, XV, and XVI;

[JWH 337;

[JWH 344;

[JWH 345; and

[JWH 405; and

[cannabinol] derivatives, except where contained in marihuana, including tetrahydro derivatives of cannabinol and 3-alkyl homologues of cannabinol or of its tetrahydro derivatives, such as:

Nabilone;

HU-210; and

HU-211;

(4) Tetramethylcyclopropyl thiazole: any compound structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent, including:

A-836,339;

(5) any compound containing a core component substituted at the 1-position to any extent, and substituted at the 3-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including:

Naphthoylindane;

Naphthoylindazole (THJ-018);

Naphthyl methyl indene (JWH-171);

Naphthoylindole (JWH-018);

Quinolinoyl pyrazole carboxylate (Quinolinyl fluoropentyl fluorophenyl pyrazole carboxylate);

Naphthoyl pyrazolopyridine; and

Naphthoylpyrrole (JWH-030);

(6) any compound containing a core component substituted at the 1-position to any extent, and substituted at the 2-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including:

Naphthoylbenzimidazole (JWH-018 Benzimidazole); and

Naphthoylimidazole;

(7) any compound containing a core

[WIN-55,212-2].

SECTION 3. Section 481.106, Health and Safety Code, is amended.

SECTION 4. The change in law made by this Act applies only to an offense committed on or after the effective date of this Act. An offense committed before the effective date of this Act is governed by the law in effect on the date the offense was committed, and the former law is continued in effect for that purpose. For purposes of this section, an offense was committed before the effective date of this Act if any element of the offense occurred before that date.

SECTION 5. This Act takes effect September 1, 2015.

component substituted at the 3-position to any extent, and substituted at the 2-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including: Naphthoyl benzothiazole; and
(8) any compound containing a core component substituted at the 9-position to any extent, and substituted at the 3-position with a link component attached to a group A component, whether or not the core component or group A component are further substituted to any extent, including: Naphthoylcarbazole (EG-018) [and
[WIN-55,212-2].

SECTION 3. Same as introduced version.

SECTION 4. Same as introduced version.

SECTION 5. Same as introduced version.